An international consensus on the use of asthma biologics in pregnancy

• Published in: The lancet respiratory medicine
• Main Authors: Naftel, Jennifer, Jackson, David J, Coleman, Matthew, d'Ancona, Grainne, Heaney, Liam G, Dennison, Paddy, Bossios, Apostolos, Rupani, Hitasha
• Format: Journal Article
• Language: English
• Published: England 28.08.2024
• ISSN: 2213-2619
• DOI: 10.1016/S2213-2600(24)00174-7

Uncontrolled asthma is associated with an increased risk of adverse perinatal outcomes. Asthma biologics reduce exacerbation frequency, are steroid sparing, and improve quality of life in people with severe asthma. However, evidence for the use and safety of asthma biologics during pregnancy is scarce, largely because pregnant women were excluded from clinical trials. To help to support clinical teams, we conducted an international modified Delphi study. 141 panellists from 32 countries who were involved in the care of people with severe asthma completed two rounds of online surveys covering key areas surrounding the use of asthma biologics in pregnancy. The results from this international Delphi study emphasise risk versus benefit discussions and shared clinical decision making, with consensus among panellists that asthma biologics can be used during conception and throughout pregnancy, initiated during pregnancy in line with prescribing criteria for non-pregnant people, and initiated or continued during breastfeeding. Collating data through international registries remains essential to inform clinical guidelines.